USPTO serial 79331138
CEBEXAN
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- BROWN, TINA
- Law office
- TMO LAW OFFICE 118- EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with CEBEXAN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations and substances; pharmaceutical preparations and substances for use in urology; pharmaceutical preparations and substances for use in gynaecology; pharmaceutical preparations and substances for use in the field of anaesthesia; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations and substances with analgesic properties; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations and substances with anti-inflammatory properties; pharmaceutical preparations and substances with antipyretic properties; pharmaceutical anti-allergic preparations and substances; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of bone fractures; pharmaceutical preparations for treating chemical imbalances; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for treating allergic rhinitis; pharmaceutical preparations for the treatment of hormonal disorders; pharmaceutical preparations for the prevention of osteoporosis; pharmaceutical preparations for treating allergies; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating hypertension; pharmaceutical preparations for treating skin diseases; pharmaceutical preparations for treating wounds; pharmaceutical preparations for ocular or intraocular surgery; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for the treatment of worms in pets; pharmaceutical preparations for peripheral nervous system; pharmaceutical preparations for use in dermatology; pharmaceutical preparations against dry skin caused by pregnancy; pharmaceutical preparations for treating chloasma; pharmaceutical preparations for activating cellular functions; pharmaceutical preparations for treating malignant tumours; pharmaceutical preparations for regulating the immune system; pharmaceutical preparations for skin moisturizing during pregnancy; pharmaceutical preparations for adapting immunity; pharmaceutical preparations for the treatment of osteoporosis; pharmaceutical preparations to prevent stretch marks; pharmaceutical preparations for preventing skin blemishes during pregnancy; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for treating Parkinson's disease; pharmaceutical preparations for the treatment of central nervous system diseases; pharmaceutical preparations for treating asthma; pharmaceutical preparations for treating sports related injuries; pharmaceutical preparations for treating cardiac arrhythmias; pharmaceutical preparations for the treatment of gout; pharmaceutical preparations for the treatment of viral diseases; pharmaceutical preparations for the treatment of digestive diseases; pharmaceutical preparations for the treatment of cardiovascular diseases; pharmaceutical preparations for the relief of insect bites; pharmaceutical preparations for human use; pharmaceutical preparations for treating eye diseases and conditions; pharmaceutical preparations for treating multiple sclerosis; pharmaceutical preparations for the treatment of bone diseases; pharmaceutical preparations for the prevention of bacteria-based diseases; pharmaceutical preparations to prevent allergies; pharmaceutical preparations for the prevention of inflammatory diseases; pharmaceutical preparations for the prevention immune system related disorders; pharmaceutical preparations for the treatment of bacteria-based diseases; pharmaceutical preparations for the prevention of disorders of the nervous system; pharmaceutical preparations for the prevention of musculoskeletal diseases; pharmaceutical preparations for the prevention of diseases of the nervous system pharmaceutical preparations for the treatment of inflammatory disorders; pharmaceutical preparations for the treatment of inflammatory diseases; pharmaceutical preparations for the treatment of endocrine system related disorders; pharmaceutical preparations for the prevention of immune system related diseases; pharmaceutical preparations for the treatment of metabolic system related diseases; pharmaceutical preparations for the prevention of the metabolic system related disorders; pharmaceutical preparations for the treatment of metabolic system related disorders; pharmaceutical preparations for the prevention of endocrine system related disorders; pharmaceutical preparations for the treatment of genitourinary system related disorders; pharmaceutical preparations for the prevention genitourinary system related disorders; pharmaceutical preparations for the prevention of metabolic system related diseases; pharmaceutical preparations for the treatment of endocrine system related diseases; pharmaceutical preparations for the prevention of respiratory system related disorders; pharmaceutical preparations for the prevention of musculoskeletal system related diseases; pharmaceutical preparations for use in organ transplantation; pharmaceutical preparations for skin wounds; hair care pharmaceutical preparations; pharmaceutical preparations for treating esophagitis; pharmaceutical preparations for the prevention of ocular disorders; pharmaceutical preparations for the treatment of genitourinary system related diseases; pharmaceutical preparations for use in tissue transplantation; pharmaceutical preparations for the treatment of bacteria-based disorders; pharmaceutical preparations for the prevention of autoimmune diseases; pharmaceutical preparations for the prevention of bacteria-based disorders; pharmaceutical preparations for the prevention of inflammatory disorders; pharmaceutical preparations for use in haematology; pharmaceutical preparations for the prevention of respiratory diseases; pharmaceutical preparations for the prevention of endocrine system related diseases; pharmaceutical preparations for the prevention of eye diseases; pharmaceutical preparations for the prevention of genitourinary system related diseases; pharmaceutical preparations for ear diseases; pharmaceutical preparations for treating epilepsy; pharmaceutical preparations for treating hypoglycaemia; pharmaceutical preparations for inhalers; pharmaceutical preparations for treating epidermal problems; pharmaceutical preparations for treating metabolism disorders; pharmaceutical preparations for treating halitosis; pharmaceutical preparations for the treatment of digestive system related diseases; pharmaceutical preparations for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the treatment of sensory organs diseases; pharmaceutical preparations for the treatment of radiation sickness symptoms; pharmaceutical preparations for the treatment of skeletal diseases; pharmaceutical preparations for treating rheumatic diseases; pharmaceutical preparations for treating arthritis; pharmaceutical products for injection; pharmaceutical products for the prevention of autoimmune diseases; pharmaceutical products for the treatment of kidney diseases; pharmaceutical products for the prevention of diabetes; pharmaceutical products for ophthalmological use; pharmaceutical products for the treatment of autoimmune diseases; pharmaceutical products for the treatment of kidney diseases; pharmaceutical products for smoking cessation; pharmaceutical products for inducing erection; pharmaceutical products for the treatment of erectile dysfunction; pharmaceutical products for animal skincare; pharmaceutical products against diabetes; pharmaceutical products against bacteria; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment of musculoskeletal diseases; pharmaceutical preparations for the treatment of hypercholesterolemia; pharmaceutical products for treating depression; pharmaceutical products for ocular use; pharmaceutical compositions; pharmaceutical moisturizing body lotion | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 5, 2024 | FINT | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jan 12, 2024 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jan 12, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 3, 2023 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jun 15, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jun 14, 2023 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Jan 12, 2023 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jan 12, 2023 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jan 12, 2023 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jul 19, 2022 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 30, 2022 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 30, 2022 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 29, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 28, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 25, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 22, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 18, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 13, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |